Literature DB >> 2004337

Clear cell sarcomas and metastatic soft tissue melanomas. A flow cytometric comparison and prognostic implications.

A K el-Naggar1, N G Ordóñez, A Sara, D McLemore, J G Batsakis.   

Abstract

Eleven soft tissue clear cell sarcomas (CCS) were examined flow cytometrically for their DNA content with a correlation of the DNA with the patients' survival. Diploidy was expressed in six sarcomas and it conferred a longer survival (mean, 68.6 months) than aneuploid sarcomas (mean, 8.2 months). For comparison, 13 metastases to soft tissues from cutaneous melanomas were assessed by flow cytometric study. The aneuploid neoplasms of both entities were categorized into low and high degree based on extent of the DNA index (DI). Low degree was defined by a DI of less than or equal to 1.5 and high degree by a DI of greater than 1.5. Significant differences in DNA content between CCS and metastatic melanomas were observed. Melanomas were preponderantly aneuploid (11/13) of high degree (mean DI, 1.7) whereas CCS manifested more diploidy (six of 11) and their aneuploidy was of a low degree (mean DI, 1.2; P = 0.001). Clear cell sarcomas and melanomas were also examined for their immunoreactivity to S-100 protein and HMB-45 antigen. All CCS reacted with S-100 protein and HMB-45. In CCS the reactions were diffuse for both in six tumors, diffuse with HMB-45 and moderate to S-100 protein in three tumors and diffuse with S-100 and moderate with HMB-45 in two tumors. All melanomas reacted diffusely to S-100 protein except for one heavily pigmented tumor which reacted only focally. The reaction to HMB-45 was diffuse in nine and focal in three melanomas. These data suggest that measurements of DNA content in CCS may be valuable in predicting clinical outcome and that there are quantitative differences in DNA content between CCS and metastatic melanoma in soft tissues.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2004337     DOI: 10.1002/1097-0142(19910415)67:8<2173::aid-cncr2820670828>3.0.co;2-o

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Molecular diagnosis of clear cell sarcoma: detection of EWS-ATF1 and MITF-M transcripts and histopathological and ultrastructural analysis of 12 cases.

Authors:  Cristina R Antonescu; Sylvia J Tschernyavsky; James M Woodruff; Achim A Jungbluth; Murray F Brennan; Marc Ladanyi
Journal:  J Mol Diagn       Date:  2002-02       Impact factor: 5.568

2.  Prognostic relevance of a novel proliferation marker, Ki-S11, for soft-tissue sarcoma. A multivariate study.

Authors:  P Rudolph; U Kellner; A Chassevent; F Collin; F Bonichon; R Parwaresch; J M Coindre
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

Review 3.  Cutaneous Melanomas: A Single Center Experience on the Usage of Immunohistochemistry Applied for the Diagnosis.

Authors:  Costantino Ricci; Emi Dika; Francesca Ambrosi; Martina Lambertini; Giulia Veronesi; Corti Barbara
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

4.  Establishment and proteomic characterization of patient-derived clear cell sarcoma xenografts and cell lines.

Authors:  Marimu Sakumoto; Rieko Oyama; Mami Takahashi; Yoko Takai; Fusako Kito; Kumiko Shiozawa; Zhiwei Qiao; Makoto Endo; Akihiko Yoshida; Akira Kawai; Tadashi Kondo
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-12-01       Impact factor: 2.416

5.  Clear cell sarcoma (malignant melanoma) of soft parts: a clinicopathologic study of 52 cases.

Authors:  O Hocar; A Le Cesne; S Berissi; P Terrier; S Bonvalot; D Vanel; A Auperin; C Le Pechoux; B Bui; J M Coindre; C Robert
Journal:  Dermatol Res Pract       Date:  2012-05-30

6.  Trabectedin is a promising antitumor agent potentially inducing melanocytic differentiation for clear cell sarcoma.

Authors:  Takaaki Nakai; Yoshinori Imura; Hironari Tamiya; Shutaro Yamada; Sho Nakai; Naohiro Yasuda; Keiko Kaneko; Hidetatsu Outani; Satoshi Takenaka; Kenichiro Hamada; Akira Myoui; Nobuhito Araki; Takafumi Ueda; Kazuyuki Itoh; Hideki Yoshikawa; Norifumi Naka
Journal:  Cancer Med       Date:  2017-07-26       Impact factor: 4.452

7.  Establishment of a novel clear cell sarcoma cell line (Hewga-CCS), and investigation of the antitumor effects of pazopanib on Hewga-CCS.

Authors:  Hidetatsu Outani; Takaaki Tanaka; Toru Wakamatsu; Yoshinori Imura; Kenichiro Hamada; Nobuhito Araki; Kazuyuki Itoh; Hideki Yoshikawa; Norifumi Naka
Journal:  BMC Cancer       Date:  2014-06-19       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.